June 20, 2012 -- Chromatrap® Pro-A, the novel solid-based matrix for chromatin immunoprecipitation assays (ChIP) has been successfully used by researchers to measure low abundant estrogen receptor (ER) transcription factor
binding on its target gene loci (XBP1) in the endometrial epithelium.
A recent study by the Reproductive Biology & Cancer Research group at the Institute of Life Science, Swansea University compared the Chromatrap performance to that of the magnetic bead based assay targeted at
ER? and the less abundant ER? isoform using a Human endometrial epithelial cell line Ishikawa, grown in the presence of Estradiol and Tamoxifen. Chromatrap was found to be as sensitive in terms of % real signal binding
of ER? on the XBP1 promoter as the bead based assay despite using a much lower chromatin input template and concentration (less than half) of ER? antibody. The performance of the Chromatrap ChIP kit was even
more robust when used to detect binding of the less abundant ER??isoform on the XBP1 promoter. Full details are available in a newly published Application Note.
For a copy of the Application Note please visit http://www.chromatrap.com/technical-library/application-notes/ or contact Porvair Filtration Group on +44-1489-864330 / +1-804-550-1600 / email firstname.lastname@example.org.
Chromatrap® is a product of Porvair Filtration Group Ltd, a wholly owned subsidiary of Porvair plc. We are dedicated to the development and supply of products for filtration and separation applications.
Our four main areas of interest are in Bioscience, Process, Nuclear and Aerospace. With offices and manufacturing sites located in the UK, Europe and the USA, combined with a world-wide network of market representatives and distributors, we pride ourselves on our continuous innovation and research to meet global demands.